Senseonics Holdings (SENS) Stock Price, Quote & News

Company Profile

Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for r...

Industry: Medical Devices

Sector: Healthcare

Phone: 301 515 7260

Fax: 833 552 7007

Website: www.senseonics.com

Address:

20451 Seneca Meadows Parkway, Germantown, United States

TELL_DSS_SCAM Sep. 8 at 12:31 AM

$SENS Robert J. Smith (50,035,000 shares, Peter J. Barris (48,863,018 shares), M. James Barrett (44,487,165 ). 17.605% (143,385,183 shares)

0 · Reply

TELL_DSS_SCAM Sep. 7 at 11:52 PM

$SENS VOTED AGAINST

0 · Reply

TELL_DSS_SCAM Sep. 7 at 11:51 PM

$SENS if your account is with Charles Schwab. Search for "Notice of Internet Availability of Proxy Materials or proxy card for Senseonics" Click on Proxy Events You can vote against

0 · Reply

TELL_DSS_SCAM Sep. 7 at 11:37 PM

$SENS if your account is with Charles Schwab Search for Notice of Internet Availability of Proxy Materials or proxy card for Senseonics click on Proxy Events You can vote against

0 · Reply

outofplano Sep. 7 at 10:54 PM

$SENS looking for upgrades thus week.

0 · Reply

White_Dragon Sep. 7 at 10:25 PM

$SENS Voted against RS today with 120,000 shares. Let's go!

1 · Reply

Sammy4 Sep. 7 at 10:16 PM

$SENS Go SENS...up trending...

1 · Reply

Sammy4 Sep. 7 at 10:11 PM

$SENS Here’s what various analyst projections and sources indicate for the 12-month outlook (i.e., roughly end of 2025): MarketBeat $1.54 $1.25 – $2.00 TipRanks $1.28 $0.50 – $2.00 Zacks – $1.00 – $2.00 average (around $1.50) StockAnalysis.com $1.63 $1.25 – $2.00 Investing.com $1.43 $1.00 – $2.00 Benzinga ~$1.44 $0.50 – $2.00 ChartMill $1.44 mean $1.01 – $2.10 HC Wainwright / Barclays (recent initiations) $1.25–$1.50 –

0 · Reply

TELL_DSS_SCAM Sep. 7 at 10:03 PM

$SENS How to Fight (Oppose) the Reverse Stock SplitAs a shareholder, you can “fight” the RSS proposal by taking steps to oppose it through voting, communication, or other actions. Here’s how:Vote Against the RSS Proposal:Use Your Proxy Control Number: The Notice specifies that shareholders of record as of August 7, 2025, can vote using their 16-digit proxy control number (e.g., 0310 4073 3188 5783, as you provided) at www.virtualshareholdermeeting.com/SENS2025SM. Log in starting at 9:45 a.m. ET on September 29, 2025, or vote beforehand via:Online: Visit the website and enter your control number. Phone: Follow instructions on your proxy card (if provided). Mail: Complete and return the proxy card, marking “AGAINST” the RSS proposal (Item 1 on the agenda).

1 · Reply

TELL_DSS_SCAM Sep. 7 at 9:20 PM

$SENS The reverse stock split (1-for-10 to 1-for-20, with a deadline of September 29, 2026) was proposed to ensure compliance with NYSE’s $1.00 minimum share price rule. Its cancellation suggests the company believed the stock price was sufficient to avoid delisting at the time, supported by positive developments like the Eversense 365 launch and recent financings ($57.5M public offering, $20.3M private offering in May 2025, and $100M loan amendment on September 3, 2025).

1 · Reply

Senseonics Holdings, Inc. (SENS) Eversense 365 Commercial Update Call (Transcript)

Sep 3, 2025, 7:22 PM EDT - 4 days ago

Ascensia Diabetes Care Signs MOU to Transfer Eversense® CGM Distribution to Strategic Partner Senseonics

Sep 3, 2025, 5:17 PM EDT - 4 days ago

Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365

Aug 6, 2025, 7:42 PM EDT - 4 weeks ago

Senseonics Holdings, Inc. (SENS) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:05 PM EDT - 4 weeks ago

Senseonics Holdings, Inc. Reports Second Quarter Financial Results

Jul 16, 2025, 4:05 PM EDT - 7 weeks ago

Senseonics Holdings, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for August 6, 2025 at 4:30 P.M. Eastern Time

Jun 4, 2025, 4:05 PM EDT - 3 months ago

Senseonics Holdings, Inc. to Host In-Person and Virtual Analyst Event at ADA 2025: Eversense® 365 Continuous Glucose Monitoring System for People with Diabetes

May 21, 2025, 5:06 PM EDT - 3 months ago

Senseonics Holdings, Inc. Announces Closing of Public Offering, Including Exercise in Full of the Underwriters' Option to Purchase Additional Shares, and Closing of Private Placement

May 21, 2025, 3:35 AM EDT - 3 months ago

Revisiting Senseonics After 4 Years: Still A Big Investment Opportunity

May 15, 2025, 11:12 PM EDT - 4 months ago

Senseonics Announces Pricing of $50 Million Public Offering of Common Stock and Concurrent Private Placement

May 15, 2025, 4:05 PM EDT - 4 months ago

Senseonics Announces Commencement of $50 Million Public Offering of Common Stock and Concurrent Private Placement

May 8, 2025, 7:55 PM EDT - 4 months ago

Senseonics Holdings, Inc. (SENS) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 4:05 PM EDT - 4 months ago

Senseonics Holdings, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for May 8, 2025 at 4:30 P.M. Eastern Time

Apr 29, 2025, 7:30 AM EDT - 4 months ago

Sequel Med Tech and Senseonics Integrate Technologies to Create First Automated Insulin Delivery (AID) System with One-Year Continuous Glucose Monitor (CGM)

Mar 3, 2025, 6:29 PM EST - 6 months ago

Senseonics Holdings, Inc. (SENS) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 4:05 PM EST - 6 months ago

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 7:30 AM EST - 6 months ago

Eversense 365 and SweetSpot Integrate Software to Optimize Diabetes Care

Feb 13, 2025, 4:05 PM EST - 7 months ago

Senseonics Holdings, Inc. to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 6, 2025, 4:05 PM EST - 7 months ago

Senseonics Completes CE Mark Submission for Eversense 365, World's Longest-lasting Continuous Glucose Monitor

Jan 8, 2025, 6:12 PM EST - 8 months ago

Senseonics Holdings, Inc. Announces Business Updates Including Preliminary 2024 Results, 365 Launch Update and Cancellation of Special Meeting

Nov 7, 2024, 6:33 PM EST - 10 months ago

Senseonics Holdings, Inc. (SENS) Q3 2024 Earnings Call Transcript

Oct 16, 2024, 4:30 PM EDT - 11 months ago

Senseonics to Host Virtual KOL Event on Eversense 365: FDA Clearance and Commercialization Plans for the World's First One-Year CGM System

Oct 10, 2024, 4:10 PM EDT - 11 months ago

Mercy Places First Commercial Eversense 365: The World's First and Only 365-Day Continuous Glucose Monitor

Oct 1, 2024, 11:00 AM EDT - 1 year ago

Eversense 365 Launches in the US: One Year. One CGM.

Sep 17, 2024, 7:00 AM EDT - 1 year ago

Eversense 365 Receives FDA Clearance: The World's First One Year CGM

Sep 6, 2024, 4:05 PM EDT - 1 year ago

Senseonics Holdings, Inc. to Participate in the Upcoming H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 6:07 PM EDT - 1 year ago

Senseonics Holdings, Inc. (SENS) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Senseonics Holdings, Inc. Reports Second Quarter 2024 Financial Results

Jul 25, 2024, 4:05 PM EDT - 1 year ago

Senseonics Holdings, Inc. Schedules Second Quarter 2024 Earnings Release and Conference Call for August 8, 2024 at 4:30 P.M. Eastern Time

Jun 21, 2024, 4:05 PM EDT - 1 year ago

Senseonics Holdings, Inc. Provides Business Update and Full Year 2024 Financial Outlook

Jun 13, 2024, 4:05 PM EDT - 1 year ago

Senseonics Holdings, Inc. to Host Business Update and Analyst Event During the American Diabetes Association's 84th Scientific Sessions

May 29, 2024, 4:05 PM EDT - 1 year ago

Senseonics Holdings, Inc. to Participate in the Sidoti Small Cap Conference

May 13, 2024, 7:52 PM EDT - 1 year ago

Senseonics Holdings, Inc. (SENS) Q1 2024 Earnings Call Transcript

May 13, 2024, 4:05 PM EDT - 1 year ago

Senseonics Holdings, Inc. Reports First Quarter 2024 Financial Results

May 13, 2024, 4:04 PM EDT - 1 year ago

Senseonics and Mercy Collaborate to Improve Diabetes Population Health Management

May 9, 2024, 4:05 PM EDT - 1 year ago

Senseonics Partners with Rimidi to Develop Innovative Diabetes Solution

May 2, 2024, 8:05 AM EDT - 1 year ago

Senseonics Holdings, Inc. to Participate in Upcoming Conferences

Apr 30, 2024, 4:05 PM EDT - 1 year ago

Senseonics Holdings, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 13, 2024 at 4:30 P.M. Eastern Time

Apr 30, 2024, 7:00 AM EDT - 1 year ago

Eversense® CGM System Receives iCGM Designation by the US FDA

Mar 12, 2024, 7:00 AM EDT - 1 year ago

SAVINGS OFFER FOR THE EVERSENSE E3 CGM EXTENDED TO COVER UNLIMITED NUMBER OF SYSTEMS

Mar 8, 2024, 8:05 AM EST - 1 year ago

Senseonics Holdings, Inc. Announces Data From the Eversense® Post Approval Study to Be Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes

Mar 6, 2024, 8:05 AM EST - 1 year ago

Senseonics Holdings, Inc. to Participate in the Oppenheimer 34th Annual Healthcare MedTech and Services Conference

Feb 29, 2024, 7:34 PM EST - 1 year ago

Senseonics Holdings, Inc. (SENS) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 4:05 PM EST - 1 year ago

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 15, 2024, 4:05 PM EST - 1 year ago

Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for February 29, 2024 at 4:30 P.M. Eastern Time

Feb 12, 2024, 7:00 AM EST - 1 year ago

Medicare Coverage Significantly Expanded for the Eversense E3 CGM System

Feb 12, 2024, 7:00 AM EST - 1 year ago

MEDICARE COVERAGE SIGNIFICANTLY EXPANDED FOR THE EVERSENSE E3 CGM SYSTEM

Feb 6, 2024, 8:00 AM EST - 1 year ago

PHC Holdings Corporation and Senseonics Announce Appointment of Brian Hansen as President of CGM at Ascensia Diabetes Care

Jan 2, 2024, 4:05 PM EST - 1 year ago

Senseonics Holdings, Inc. Announces Business Updates

Nov 9, 2023, 6:50 PM EST - 1 year ago

Senseonics Holdings, Inc. (SENS) Q3 2023 Earnings Call Transcript

TELL_DSS_SCAM Sep. 8 at 12:31 AM

$SENS Robert J. Smith (50,035,000 shares, Peter J. Barris (48,863,018 shares), M. James Barrett (44,487,165 ). 17.605% (143,385,183 shares)

0 · Reply

TELL_DSS_SCAM Sep. 7 at 11:52 PM

$SENS VOTED AGAINST

0 · Reply

TELL_DSS_SCAM Sep. 7 at 11:51 PM

$SENS if your account is with Charles Schwab. Search for "Notice of Internet Availability of Proxy Materials or proxy card for Senseonics" Click on Proxy Events You can vote against

0 · Reply

TELL_DSS_SCAM Sep. 7 at 11:37 PM

$SENS if your account is with Charles Schwab Search for Notice of Internet Availability of Proxy Materials or proxy card for Senseonics click on Proxy Events You can vote against

0 · Reply

outofplano Sep. 7 at 10:54 PM

$SENS looking for upgrades thus week.

0 · Reply

White_Dragon Sep. 7 at 10:25 PM

$SENS Voted against RS today with 120,000 shares. Let's go!

1 · Reply

Sammy4 Sep. 7 at 10:16 PM

$SENS Go SENS...up trending...

1 · Reply

Sammy4 Sep. 7 at 10:11 PM

0 · Reply

TELL_DSS_SCAM Sep. 7 at 10:03 PM

1 · Reply

TELL_DSS_SCAM Sep. 7 at 9:20 PM

1 · Reply

TELL_DSS_SCAM Sep. 7 at 9:20 PM

$SENS ClarificationNo New Reverse Stock Split Proposal: As of September 7, 2025, 2:18 PM PDT, there is no evidence of a new reverse stock split proposal beyond the one outlined in the August 18, 2025, DEF 14A, which was canceled on January 8, 2025. No subsequent SEC filings, press releases, or credible sources (web or X posts) indicate a renewed effort for a reverse split. Current NYSE Compliance Status: Senseonics is not currently reported as non-compliant with NYSE American listing standards. No formal deficiency notice for the minimum share price or other standards (e.g., stockholders’ equity, public float) has been documented. However, the stock price below $1.00 ($0.4575) could lead to a future deficiency notice if it persists for 30 consecutive trading days without correction. Why the Proposal Existed:

0 · Reply

TELL_DSS_SCAM Sep. 7 at 9:17 PM

$SENS NYSE American typically allows a six-month cure period after issuing a deficiency notice, during which a company can regain compliance by achieving a closing price of at least $1.00 for 10 consecutive trading days or by taking actions like a reverse stock split. Since no deficiency notice is documented, Senseonics is not currently non-compliant on this front.

0 · Reply

TELL_DSS_SCAM Sep. 7 at 9:17 PM

$SENS Current Compliance with NYSE Listing StandardsBased on the provided information and available data, here’s the status of Senseonics’ compliance with NYSE American listing standards as of September 7, 2025:Minimum Share Price Requirement:The most recent stock price data from September 5, 2025, shows SENS closing at $0.4575 with an after-hours price of $0.4511, both below the NYSE American’s $1.00 threshold. However, there is no evidence in the provided data or recent sources (SEC filings, press releases, or X posts) that Senseonics has received a formal deficiency notice from NYSE American for failing to meet the minimum share price requirement. The cancellation of the reverse stock split proposal in January 2025 suggests that the stock price had improved enough to avoid immediate non-compliance concerns. However, the current price below $1.00 indicates a potential risk of future non-compliance if it persists for 30 consecutive trading days without corrective action.

0 · Reply

TELL_DSS_SCAM Sep. 7 at 9:07 PM

$SENS Cancellation of Reverse Stock Split: On January 8, 2025, Senseonics canceled the special shareholder meeting scheduled for January 10, 2025 (not September 29, 2025, as initially planned in the DEF 14A), citing a recent appreciation in the company’s share price and shareholder feedback. This suggests that the stock price had risen sufficiently to mitigate the immediate risk of non-compliance with NYSE American’s minimum price requirement. As of September 5, 2025, the stock price was reported at $0.4575 (close) and $0.4511 (after hours), which is still below $1.00, but no explicit notice of non-compliance or delisting has been issued.

0 · Reply

Sammy4 Sep. 7 at 9:06 PM

$SENS

0 · Reply

TELL_DSS_SCAM Sep. 7 at 9:04 PM

$SENS from Grok Current Status: Senseonics’ stock price recovery and the cancellation of the reverse split suggest the company is currently in compliance with NYSE American listing requirements. Recent developments, such as the Eversense 365 launch and a $100 million loan agreement amendment announced on September 3, 2025, indicate focus on operational growth rather than a new reverse split. No new proxy statements or filings have surfaced to suggest a renewed effort for a reverse stock split.

0 · Reply

HorseRacer Sep. 7 at 1:54 PM

$SENS My vote is in .... NO to the RS.

0 · Reply

Sammy4 Sep. 7 at 9:47 AM

$SENS

0 · Reply

Takecares Sep. 7 at 8:40 AM

$SENS $SENS : I believe this is one of good news at Senseonics. Go Senseonics ⬅️ "Quoted " : Profitability" is expected to improve based on last year’s results." *Signing of the Memorandum of Understanding on the Business Transfer of a Consolidated Subsidiary. PHC Holdings Corporation (hereinafter referred to as "the Company") hereby announces that at the Board of Directors meeting on September 4, 2025 (JST),a resolution was passed to sign the memorandum of understanding to transfer the commercial operation of Eversense Continuous Glucose Monitoring (CGM) System. *Schedule （１） Date of Memorandum of Understanding Signing September 4, 2025（２)Date of Definitive Agreement Signing October 31, 2025 (tentative)（３) Date of Business Transfer Completion January 1, 2026 (tentative) * Future Outlook : The business performance of the relevant operations in the previous fiscal year indicates that profitability is expected to improve based on last year’s results. //Quoted ends

0 · Reply

Sammy4 Sep. 7 at 7:47 AM

$SENS

0 · Reply

Thi20 Sep. 7 at 7:22 AM

$SENS

1 · Reply

TELL_DSS_SCAM Sep. 7 at 7:16 AM

$SENS file a complaint with the SEC and CC: -The Whitehouse -The SEC Division of Corporation Finance (100 F Street, NE, Washington, DC 20549, CIK: 0001616543) -Tim Goodnow, President and CEO -Mukul Jain, Chief Operating Officer -Dr. Francine R. Kaufman, Chief Medical Officer -Rick Sullivan, Chief Financial Officer -Abhi Chavan, Vice President of Engineering, Research and Development -Investor Relations, Senseonics Holdings, Inc. - Board of Directors, “Stephen P. DeFalco, Edward J. Fiorentino, Fran Kaufman, MD, Sharon D. Larkin, Douglas S. Prince, Douglas A. Roeder, Koichiro Sato, Timothy T. Goodnow, PhD, Steven V. Edelman, MD, Brian Hansen”

0 · Reply

Market Cap	372.72M
Revenue (ttm)	22.47M
Net Income (ttm)	-78.62M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-349.89%
Debt to Equity Ratio	0.37

Volume	3,765,600
Avg Vol	6,366,130
Day's Range	N/A - N/A
Shares Out	814.68M
Stochastic %K	24%
Beta	0.93
Analysts	Sell
Price Target	$1.43